23:46 , Mar 21, 2019 |  BC Week In Review  |  Company News

NICE recommends Darzalex to treat MM, almost two years after European approval

The U.K.'s NICE recommended this month that Janssen Biotech's Darzalex daratumumab be available through the Cancer Drugs Fund as a second-line treatment for relapsed multiple myeloma in combination with bortezomib plus dexamethasone. The European Commission...
02:46 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
20:05 , Feb 25, 2019 |  BC Extra  |  Clinical News

Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to treat relapsed or refractory multiple myeloma. Partner Janssen Biotech Inc. told...
01:35 , Feb 15, 2019 |  BC Week In Review  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
21:47 , Feb 14, 2019 |  BC Extra  |  Company News

India's Glenmark spinning out innovative assets into U.S. unit

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) will spin out its innovation business to help accelerate its pipeline towards commercialization. The spinout will be a wholly owned subsidiary based in the U.S and have a new CEO...
18:51 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38 met the primary endpoint in...
06:00 , Feb 5, 2019 |  BC Extra  |  Clinical News

Sanofi's isatuximab meets survival endpoint for third-line MM

Sanofi (Euronext:SAN; NASDAQ:SNY) said it will submit regulatory applications to FDA and EMA this half for isatuximab in relapsed or refractory multiple myeloma after the humanized IgG1 mAb against CD38 met the primary endpoint in...
17:39 , Jan 11, 2019 |  BC Week In Review  |  Company News

Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a $75 million milestone payment from partner Janssen Biotech Inc. Last February, Genmab projected that 2018...
21:05 , Jan 10, 2019 |  BC Innovations  |  Emerging Company Profile

Kleo: small molecule immuno-oncology

Kleo Pharmaceuticals Inc. is tapping small molecules' advantages over biologics by synthesizing compounds that mimic or modify the functions of antibodies as cancer immunotherapies. The company spun out of Yale University in 2015 with IP...
22:44 , Jan 8, 2019 |  BC Extra  |  Company News

Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a $75 million milestone payment from partner Janssen Biotech Inc. Last February, Genmab projected that 2018...